Several studies revealed reduced expression of HLTF caused by promoter hypermethylation in colon, esophageal, gastric, and uterine cancers, suggesting that HLTF silencing conferred a selective growth advantage [222]. The gene discussed is HLTF; the disease is uterine cancer.